Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2552898 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PegIntron 1.5 µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2) PegIntron 1µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3) PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day.
PegIntron Dose will be administered once weekly subcutaneously on the same day of the week:
Screening 2 Weight 40-50 kg Volume to Inject (mL) 0.22; Screening 2 Weight 51-60 kg Volume to Inject (mL) 0.28; Screening 2 Weight 61-75 kg Volume to Inject (mL) 0.33; Screening 2 Weight 76-85 kg Volume to Inject (mL) 0.41; Screening 2 Weight 86-104 kg Volume to Inject (mL) 0.48; Screening 2 Weight 105-125 kg Volume to Inject (mL) 0.58 from two vials
REBETOL Dosage (for Use With PegIntron):
Screening 2 Weight 40-65 kg Daily Dose 800 mg; Screening 2 Weight >65-85 kg Daily Dose 1000 mg; Screening 2 Weight >85-105 kg Daily Dose 1200 mg; Screening 2 Weight >105-125 kg Daily Dose 1400 mg
The PEGASYS dose of 1 mL (180 µg) will be administered once weekly subcutaneously on the same day of the week
COPEGUS Dosage (for Use With PEGASYS):
Screening 2 Weight <75 kg Daily Dose 1000 mg; Screening 2 Weight > or = 75 kg Daily Dose 1200mg
NOTE: Double Blind for PegIntron; Open Label for REBETOL, PEGASYS and COPEGUS
NOTE: REBETOL is the Schering-Plough brand name for ribavirin. COPEGUS is the Hoffman-La Roche brand name for ribavirin.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PegIntron 1.5 ug/kg/wk plus REBETOL | Experimental | PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up |
|
| PegIntron 1.0 ug/kg/wk plus REBETOL | Experimental | PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up |
|
| PEGASYS 180 ug/wk Plus COPEGUS | Active Comparator | PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PegIntron (peginterferon alfa-2b; SCH 54031) | Biological | 1.5 ug/kg/week subcutaneously (SC) for 48 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Sustained Virologic Response (SVR) Rate | SVR rate is the percentage of participants with undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at the end of the 24-week post-treatment follow-up. | Assessed at the end of a 24-week post-treatment follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change From Baseline in the Log Viral Load at Treatment Week 4 | The difference between viral load levels in the blood at the start of the study and Treatment Week 4, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group. | Assessed at Baseline and Treatment Week 4 |
Not provided
INCLUSION CRITERIA:
Previously untreated adults with chronic hepatitis C (hepatitis C virus ribonucleic acid [HCV RNA] quantitative polymerase chain reaction [qPCR] plasma positive)
Individuals with HCV genotype 1 (mixed 1a/1b is acceptable)
Compensated liver disease
Pretreatment liver biopsy slides available
Adults aged 18-70
Individuals weighing 88-275 pounds (40-125 kg)
Free from substance abuse for past 2 years
Those suffering from diabetes and/or hypertension must have normal eye exams and retinal photographs (these will be done as part of the study before hepatitis C treatment is given)
Patients and partners of patients willing to use adequate contraception during the course of the study
Hematology laboratory results of:
Chemistry laboratory results of:
EXCLUSION CRITERIA:
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19625712 | Result | McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22. | |
| 21488082 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Enrolled 4469 subjects; Randomized 3083; Treated 3070
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | PegIntron 1.5 ug/kg/wk Plus REBETOL | PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up |
| FG001 | PegIntron 1.0 ug/kg/wk Plus REBETOL |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| PegIntron (peginterferon alfa-2b; SCH 54031) | Biological | 1.0 ug/kg/week SC for 48 weeks |
|
|
| REBETOL (ribavirin; SCH 18908) | Drug | weight based dose 800-1400 mg/day orally (PO) for 48 weeks |
|
|
| PEGASYS (peginterferon alfa-2a) | Biological | 180 ug/week SC administered for 48 weeks |
|
|
| COPEGUS (ribavirin) | Drug | 1000-1200 mg/day PO for 48 weeks |
|
|
| Virologic Response Rate at Treatment Week 12 |
Percentage of participants with undetectable hepatitis C RNA (HCV-RNA) at Treatment Week 12 |
| Assessed at Treatment Week 12 |
| Mean Change From Baseline in the Log Viral Load at Treatment Week 2 | The difference between viral load levels in the blood at the start of the study and Treatment Week 2, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group. | Assessed at Baseline and Treatment Week 2 |
| Derived |
| Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; IDEAL Study Team. Racial differences in hepatitis C treatment eligibility. Hepatology. 2011 Jul;54(1):70-8. doi: 10.1002/hep.24358. |
PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up |
| FG002 | PEGASYS 180 ug/wk Plus COPEGUS | PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | PegIntron 1.5 ug/kg/wk Plus REBETOL | PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up |
| BG001 | PegIntron 1.0 ug/kg/wk Plus REBETOL | PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up |
| BG002 | PEGASYS 180 ug/wk Plus COPEGUS | PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Sustained Virologic Response (SVR) Rate | SVR rate is the percentage of participants with undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at the end of the 24-week post-treatment follow-up. | Intent-to-Treat [ITT] Population defined as subjects who received at least one dose of study medication | Posted | Number | Percentage of participants | Assessed at the end of a 24-week post-treatment follow-up |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in the Log Viral Load at Treatment Week 4 | The difference between viral load levels in the blood at the start of the study and Treatment Week 4, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group. | ITT Population defined as subjects who received at least one dose of study medication | Posted | Mean | Standard Deviation | Log10 IU/mL | Assessed at Baseline and Treatment Week 4 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Virologic Response Rate at Treatment Week 12 | Percentage of participants with undetectable hepatitis C RNA (HCV-RNA) at Treatment Week 12 | ITT Population defined as subjects who received at least one dose of study medication | Posted | Number | Percentage of participants | Assessed at Treatment Week 12 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in the Log Viral Load at Treatment Week 2 | The difference between viral load levels in the blood at the start of the study and Treatment Week 2, expressed in terms of a logarithmic scale with base 10, and averaged for all the participants in each treatment group. | ITT Population defined as subjects who received at least one dose of study medication | Posted | Mean | Standard Deviation | Log10 IU/mL | Assessed at Baseline and Treatment Week 2 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | PegIntron 1.5 ug/kg/wk Plus REBETOL | 88 | 1,019 | 996 | 1,019 | |||
| EG001 | PegIntron 1.0 ug/kg/wk Plus REBETOL | 94 | 1,016 | 1,000 | 1,016 | |||
| EG002 | PEGASYS 180 ug/wk Plus COPEGUS | 121 | 1,035 | 1,018 | 1,035 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ANAEMIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| APLASTIC ANAEMIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DISSEMINATED INTRAVASCULAR COAGULATION | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HAEMOLYTIC ANAEMIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| LEUKOPENIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| LYMPHADENITIS | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| LYMPHADENOPATHY | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| NEUTROPENIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PANCYTOPENIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| THROMBOCYTOPENIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| THROMBOTIC THROMBOCYTOPENIC PURPURA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ACUTE MYOCARDIAL INFARCTION | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ATRIAL FIBRILLATION | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ATRIAL TACHYCARDIA | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ATRIOVENTRICULAR BLOCK COMPLETE | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CARDIAC FAILURE CONGESTIVE | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CARDIO-RESPIRATORY ARREST | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CARDIOMYOPATHY | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CORONARY ARTERY DISEASE | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CORONARY ARTERY RESTENOSIS | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CORONARY ARTERY STENOSIS | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CYANOSIS | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| MYOCARDIAL INFARCTION | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PALPITATIONS | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PERICARDITIS | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| VENTRICULAR FIBRILLATION | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| WOLFF-PARKINSON-WHITE SYNDROME | Cardiac disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HEARING IMPAIRED | Ear and labyrinth disorders | MedDRA 10.1 | Systematic Assessment |
| |
| VERTIGO | Ear and labyrinth disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ADRENAL INSUFFICIENCY | Endocrine disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPOTHYROIDISM | Endocrine disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CATARACT | Eye disorders | MedDRA 10.1 | Systematic Assessment |
| |
| MACULOPATHY | Eye disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PAPILLOEDEMA | Eye disorders | MedDRA 10.1 | Systematic Assessment |
| |
| RETINAL DETACHMENT | Eye disorders | MedDRA 10.1 | Systematic Assessment |
| |
| RETINAL HAEMORRHAGE | Eye disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ABDOMINAL HERNIA | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| APPENDICITIS PERFORATED | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| COLITIS | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| COLITIS ISCHAEMIC | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DIARRHOEA | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| EROSIVE OESOPHAGITIS | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| FOOD POISONING | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| GASTRIC ULCER | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| GASTRITIS EROSIVE | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| GASTROINTESTINAL PAIN | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| GASTROOESOPHAGEAL REFLUX DISEASE | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HAEMATEMESIS | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HAEMORRHOIDAL HAEMORRHAGE | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HAEMORRHOIDS | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ILEUS | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| INGUINAL HERNIA | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| IRRITABLE BOWEL SYNDROME | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| LARGE INTESTINAL OBSTRUCTION | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| MALLORY-WEISS SYNDROME | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| NAUSEA | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| OESOPHAGEAL VARICES HAEMORRHAGE | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PANCREATIC CYST | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PANCREATIC ENLARGEMENT | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PANCREATIC MASS | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PANCREATITIS | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PANCREATITIS ACUTE | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PERITONEAL HAEMORRHAGE | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| RECTAL HAEMORRHAGE | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SALIVARY DUCT OBSTRUCTION | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SMALL INTESTINAL OBSTRUCTION | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| VOMITING | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CHEST DISCOMFORT | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CHEST PAIN | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DEATH | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DRUG WITHDRAWAL SYNDROME | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| FACE OEDEMA | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| FATIGUE | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HERNIA OBSTRUCTIVE | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| NON-CARDIAC CHEST PAIN | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PYREXIA | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| BILE DUCT STENOSIS | Hepatobiliary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| BILE DUCT STONE | Hepatobiliary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| BILIARY DYSKINESIA | Hepatobiliary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CHOLECYSTITIS | Hepatobiliary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CHOLECYSTITIS ACUTE | Hepatobiliary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CHOLECYSTITIS CHRONIC | Hepatobiliary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CHOLELITHIASIS | Hepatobiliary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| JAUNDICE | Hepatobiliary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PORTAL HYPERTENSIVE GASTROPATHY | Hepatobiliary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPERSENSITIVITY | Immune system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SARCOIDOSIS | Immune system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ABDOMINAL WALL INFECTION | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| ABSCESS LIMB | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| ANOGENITAL WARTS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| APPENDICITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| BLASTOMYCOSIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| BRONCHITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| BURSITIS INFECTIVE STAPHYLOCOCCAL | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| CELLULITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| CHOLECYSTITIS INFECTIVE | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| DIVERTICULITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| ENCEPHALITIS VIRAL | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| ENTEROCOLITIS INFECTIOUS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| ESCHERICHIA SEPSIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| FOLLICULITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| GASTROENTERITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| GASTROENTERITIS VIRAL | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| HERPES OESOPHAGITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| INFECTION | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| INFECTIVE TENOSYNOVITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| INJECTION SITE ABSCESS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| INJECTION SITE CELLULITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| KIDNEY INFECTION | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| LOBAR PNEUMONIA | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| LUNG ABSCESS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| MENINGITIS VIRAL | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| ORCHITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| PERITONEAL ABSCESS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| PNEUMONIA | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| PNEUMONIA STREPTOCOCCAL | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| PYELONEPHRITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| SEPSIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| SEPSIS SYNDROME | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| SINUSITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| STAPHYLOCOCCAL ABSCESS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| STAPHYLOCOCCAL INFECTION | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| STAPHYLOCOCCAL SKIN INFECTION | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| SUBCUTANEOUS ABSCESS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| URINARY TRACT INFECTION | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| VIRAL INFECTION | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| WOUND INFECTION STAPHYLOCOCCAL | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| ACCIDENTAL OVERDOSE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| ALCOHOL POISONING | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| ANIMAL BITE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| ARTHROPOD BITE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| BACK INJURY | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| CERVICAL VERTEBRAL FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| CLAVICLE FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| CONCUSSION | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| DRUG TOXICITY | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| FACIAL BONES FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| FALL | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| FEMUR FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| GUN SHOT WOUND | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| HAND FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| HEAD INJURY | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| HEPATIC HAEMATOMA | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| HIP FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| HUMAN BITE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| JAW FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| LUNG INJURY | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| MUSCLE STRAIN | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| OVERDOSE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| PELVIC FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| POST PROCEDURAL BILE LEAK | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| POST PROCEDURAL HAEMATOMA | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| RIB FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| ROAD TRAFFIC ACCIDENT | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| SCAPULA FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| SKIN LACERATION | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| SPINAL FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| SPLENIC RUPTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| THERAPEUTIC AGENT TOXICITY | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| THERMAL BURN | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| TOOTH FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| TRAUMATIC BRAIN INJURY | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| WRIST FRACTURE | Injury, poisoning and procedural complications | MedDRA 10.1 | Systematic Assessment |
| |
| ELECTROCARDIOGRAM ST SEGMENT DEPRESSION | Investigations | MedDRA 10.1 | Systematic Assessment |
| |
| GRIP STRENGTH DECREASED | Investigations | MedDRA 10.1 | Systematic Assessment |
| |
| LIVER FUNCTION TEST ABNORMAL | Investigations | MedDRA 10.1 | Systematic Assessment |
| |
| WHITE BLOOD CELL COUNT DECREASED | Investigations | MedDRA 10.1 | Systematic Assessment |
| |
| DEHYDRATION | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DIABETES MELLITUS | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DIABETIC KETOACIDOSIS | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPERCALCAEMIA | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPERGLYCAEMIA | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPONATRAEMIA | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPOVOLAEMIA | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| TYPE 2 DIABETES MELLITUS | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ARTHRALGIA | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| BACK PAIN | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| BURSITIS | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| GOUTY ARTHRITIS | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| INTERVERTEBRAL DISC PROTRUSION | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| JOINT INSTABILITY | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| MUSCULOSKELETAL CHEST PAIN | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| MUSCULOSKELETAL PAIN | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| NECK PAIN | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| OSTEOARTHRITIS | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PAIN IN EXTREMITY | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| RHABDOMYOLYSIS | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SPINAL OSTEOARTHRITIS | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| WEIGHT BEARING DIFFICULTY | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ACOUSTIC NEUROMA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| ACUTE MYELOID LEUKAEMIA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| BLADDER NEOPLASM | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| BREAST CANCER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| HAEMANGIOMA OF LIVER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| HEPATIC NEOPLASM MALIGNANT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| LUNG NEOPLASM | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| MALIGNANT MELANOMA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| MALIGNANT NEOPLASM OF AMPULLA OF VATER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| METASTASES TO LIVER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| OROPHARYNGEAL CANCER STAGE UNSPECIFIED | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| OVARIAN ADENOMA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| PANCREATIC CARCINOMA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| UTERINE LEIOMYOMA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 10.1 | Systematic Assessment |
| |
| AKATHISIA | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ANOXIC ENCEPHALOPATHY | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CEREBRAL HAEMORRHAGE | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CEREBROVASCULAR ACCIDENT | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| COMA | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CONVULSION | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DIZZINESS | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DYSARTHRIA | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ENCEPHALOPATHY | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| FACIAL PALSY | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPOAESTHESIA | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| INTRACRANIAL ANEURYSM | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| LOSS OF CONSCIOUSNESS | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| MIGRAINE | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| NEUROPATHY PERIPHERAL | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PARAESTHESIA | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PARAPLEGIA | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PERONEAL NERVE PALSY | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PRESYNCOPE | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SCIATICA | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SPINAL CORD COMPRESSION | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SPINAL CORD INFARCTION | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SYNCOPE | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SYNCOPE VASOVAGAL | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ABORTION SPONTANEOUS | Pregnancy, puerperium and perinatal conditions | MedDRA 10.1 | Systematic Assessment |
| |
| ACUTE PSYCHOSIS | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| AFFECTIVE DISORDER | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| AGITATION | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ANGER | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ANXIETY | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| COMPLETED SUICIDE | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DEPENDENCE | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DEPRESSION | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DISORIENTATION | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DRUG ABUSE | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DRUG DEPENDENCE | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HALLUCINATION | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HALLUCINATION, AUDITORY | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HALLUCINATION, VISUAL | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HOMICIDAL IDEATION | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| MENTAL STATUS CHANGES | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PARANOIA | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PSYCHOTIC DISORDER | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SUICIDAL IDEATION | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| SUICIDE ATTEMPT | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| BLADDER DISORDER | Renal and urinary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CALCULUS URETERIC | Renal and urinary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| NEPHROLITHIASIS | Renal and urinary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| NEPHROTIC SYNDROME | Renal and urinary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| RENAL FAILURE | Renal and urinary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| RENAL FAILURE ACUTE | Renal and urinary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| RENAL PAIN | Renal and urinary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| URINARY INCONTINENCE | Renal and urinary disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CERVICAL DYSPLASIA | Reproductive system and breast disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CYSTOCELE | Reproductive system and breast disorders | MedDRA 10.1 | Systematic Assessment |
| |
| RECTOCELE | Reproductive system and breast disorders | MedDRA 10.1 | Systematic Assessment |
| |
| UTERINE HAEMORRHAGE | Reproductive system and breast disorders | MedDRA 10.1 | Systematic Assessment |
| |
| VAGINAL HAEMORRHAGE | Reproductive system and breast disorders | MedDRA 10.1 | Systematic Assessment |
| |
| VAGINAL PROLAPSE | Reproductive system and breast disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ACUTE RESPIRATORY DISTRESS SYNDROME | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ACUTE RESPIRATORY FAILURE | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ASTHMA | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DYSPNOEA | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| EPISTAXIS | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPOXIA | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PLEURISY | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PNEUMONIA ASPIRATION | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PULMONARY EMBOLISM | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PULMONARY HYPERTENSION | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PULMONARY SARCOIDOSIS | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ERYTHEMA MULTIFORME | Skin and subcutaneous tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PHYSICAL ASSAULT | Social circumstances | MedDRA 10.1 | Systematic Assessment |
| |
| CYSTOPEXY | Surgical and medical procedures | MedDRA 10.1 | Systematic Assessment |
| |
| HYSTERECTOMY | Surgical and medical procedures | MedDRA 10.1 | Systematic Assessment |
| |
| RECTOCELE REPAIR | Surgical and medical procedures | MedDRA 10.1 | Systematic Assessment |
| |
| SALPINGO-OOPHORECTOMY UNILATERAL | Surgical and medical procedures | MedDRA 10.1 | Systematic Assessment |
| |
| SPINAL FUSION SURGERY | Surgical and medical procedures | MedDRA 10.1 | Systematic Assessment |
| |
| DEEP VEIN THROMBOSIS | Vascular disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPERTENSION | Vascular disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPOTENSION | Vascular disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ORTHOSTATIC HYPOTENSION | Vascular disorders | MedDRA 10.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ANAEMIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| LEUKOPENIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| NEUTROPENIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| THROMBOCYTOPENIA | Blood and lymphatic system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HYPOTHYROIDISM | Endocrine disorders | MedDRA 10.1 | Systematic Assessment |
| |
| VISION BLURRED | Eye disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ABDOMINAL PAIN UPPER | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CONSTIPATION | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DIARRHOEA | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DRY MOUTH | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DYSPEPSIA | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| NAUSEA | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| VOMITING | Gastrointestinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ASTHENIA | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| CHILLS | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| FATIGUE | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| INFLUENZA LIKE ILLNESS | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| INJECTION SITE ERYTHEMA | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| INJECTION SITE REACTION | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| IRRITABILITY | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PAIN | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PYREXIA | General disorders | MedDRA 10.1 | Systematic Assessment |
| |
| BRONCHITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| SINUSITIS | Infections and infestations | MedDRA 10.1 | Systematic Assessment |
| |
| WEIGHT DECREASED | Investigations | MedDRA 10.1 | Systematic Assessment |
| |
| ANOREXIA | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DECREASED APPETITE | Metabolism and nutrition disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ARTHRALGIA | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| BACK PAIN | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| MUSCLE SPASMS | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| MYALGIA | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PAIN IN EXTREMITY | Musculoskeletal and connective tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DISTURBANCE IN ATTENTION | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DIZZINESS | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DYSGEUSIA | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| HEADACHE | Nervous system disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ANXIETY | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DEPRESSION | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| INSOMNIA | Psychiatric disorders | MedDRA 10.1 | Systematic Assessment |
| |
| COUGH | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DYSPNOEA | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DYSPNOEA EXERTIONAL | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PHARYNGOLARYNGEAL PAIN | Respiratory, thoracic and mediastinal disorders | MedDRA 10.1 | Systematic Assessment |
| |
| ALOPECIA | Skin and subcutaneous tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| DRY SKIN | Skin and subcutaneous tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| PRURITUS | Skin and subcutaneous tissue disorders | MedDRA 10.1 | Systematic Assessment |
| |
| RASH | Skin and subcutaneous tissue disorders | MedDRA 10.1 | Systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Senior Vice President, Global Clinical Development | Merck Sharp & Dohme Corp. | ClinicalTrialsDisclosure@merck.com |
| ID | Term |
|---|---|
| D019698 | Hepatitis C, Chronic |
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C417083 | peginterferon alfa-2b |
| D012254 | Ribavirin |
| C100416 | peginterferon alfa-2a |
| ID | Term |
|---|---|
| D012263 | Ribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
Not provided
Not provided
| Male |
|
| Superiority or Other |
| Regression, Logistic | The p-value is based on the logistic regression model that includes treatment and baseline stratification factors (viral load and race). | 0.195 | Holm's method for multiplicity adjustment was to be used to control the overall Type I error rate at α = 0.05. However, since there was no significant difference in the overall SVR rates between the three groups, no Type-1 error adjustment was made. | Odds Ratio (OR) | 1.08 | 95 | 0.90 | 1.30 | The odds ratio is based on the logistic regression model that includes treatment and baseline stratification factors: viral load (≤600,000 IU/mL vs >600,000 IU/mL) and race (Black vs non-Black). | Superiority or Other |
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
|